Best hospitals for lymphoma: An evidence-based guide to specialist cancer centers

The best hospitals for lymphoma are generally distinguished by specialist hematology teams, multidisciplinary diagnosis, transplantation and cellular-therapy capabilities, and participation in research. National rankings can provide context, but the most appropriate center depends on whether the diagnosis is Hodgkin lymphoma, non-Hodgkin lymphoma, an aggressive subtype, a rare disease, or relapsed disease.

How national rankings provide context

The University of Texas MD Anderson Cancer Center was ranked the No. 1 U.S. cancer hospital in the 2026-2027 U.S. News and World Report cancer rankings, according to reporting from Healio. The institution has ranked first 22 times in 25 years and first or second every year since the rankings began in 1990. Memorial Sloan Kettering Cancer Center ranked second for cancer care in the same report. 1

Rankings measure broad cancer-care performance rather than guaranteeing a particular result for an individual lymphoma patient. The same 2026-2027 top cancer-care group included Dana-Farber Brigham Cancer Center, Mayo Clinic in Rochester, Massachusetts General Hospital, Johns Hopkins Hospital, the Hospital of the University of Pennsylvania, Northwestern Memorial Hospital, Stanford Hospital, Mount Sinai Hospital, and UCSF Medical Center. 1 A lymphoma-specific consultation remains more informative than a general institutional ranking.

Memorial Sloan Kettering and MD Anderson

Memorial Sloan Kettering in New York is a cancer-focused institution that describes its model as personalized care supported by research and coordinated care teams. Its institutional materials state that discoveries from laboratory research lead to new treatments, while its public rankings information identifies MSK as the No. 2 cancer hospital nationally in 2026-2027 and the top cancer center in the Northeast and New York metropolitan area. 2

MD Anderson's repeated position at the top of national cancer rankings makes it a major reference point for patients evaluating comprehensive cancer centers. For lymphoma, the practical value of a large specialist institution includes access to hematology expertise, pathology review, complex treatment planning, and research programs, although the supplied ranking data does not establish that one hospital is superior for every lymphoma subtype or every patient. 1

Centers with multidisciplinary lymphoma expertise

Mayo Clinic in Rochester is identified in the research material as using a collaborative, team-based approach for complex and rare blood cancers. This structure is relevant when diagnosis involves unusual pathology, several organ systems, or treatment decisions requiring hematology, oncology, imaging, transplantation, and supportive-care input. A multidisciplinary process can also help coordinate second opinions and individualized treatment planning. 3

Johns Hopkins Hospital is described as providing comprehensive, evidence-based lymphoma care that integrates advanced diagnostic imaging with targeted systemic therapies. Cleveland Clinic's Taussig Cancer Institute is identified as treating Hodgkin and non-Hodgkin lymphoma with attention to advanced protocols and survivorship. These descriptions support comparing diagnostic depth and follow-up services, not simply counting hospital awards or relying on patient anecdotes. 5 6

Research, clinical trials, and cellular therapy

Dana-Farber Brigham Cancer Center is recognized in the supplied research for leadership in lymphoma clinical trials and innovative CAR T-cell therapy. Mass General Cancer Center also has a dedicated Center for Lymphoma, led by hematologist-oncologist Jeremy Abramson, whose stated interests include lymphoid malignancies, Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphoid leukemias, and trials of immunotherapies. 4 13

Cellular therapy is not a single treatment suitable for every patient. Sheba Medical Center in Israel describes CAR T-cell therapy for selected relapsed or refractory lymphomas as part of a research program, with eligibility determined case by case. Its listed areas include diffuse large B-cell, follicular, and mantle cell lymphomas, while primary central nervous system and Burkitt lymphoma applications are being evaluated in research protocols. 11

Transplantation and rare or aggressive lymphoma

City of Hope in California is identified as specializing in bone marrow and stem cell transplantation for refractory lymphoma cases. That capability may matter when a patient is being evaluated for an autologous or allogeneic transplant, but treatment suitability depends on disease subtype, prior therapy, response, health status, and the treating team's assessment. The research supplied does not provide a universal success rate for transplantation at City of Hope. 8

Fred Hutchinson Cancer Center, now part of the Seattle Cancer Care Alliance in the supplied research description, is associated with immunotherapy and long-term research into aggressive hematologic malignancies. University of Chicago Medicine is identified as providing expertise for high-risk and aggressive lymphoma through established chemotherapy and novel clinical investigation. These centers illustrate why subtype-specific experience can be more relevant than a general cancer score. 9 10

NCI designation and center-selection criteria

The National Cancer Institute states that NCI-Designated Cancer Centers meet rigorous standards involving cancer research, clinical care, and scientific leadership. Stephenson Cancer Center at OU Health is described as Oklahoma's only NCI-Designated Cancer Center and offers multidisciplinary hematology, oncology, transplantation, and cellular-therapy specialists for lymphoma. NCI designation signals research infrastructure and peer-reviewed oversight, but it does not eliminate the need to assess a center's experience with the specific lymphoma subtype. 7 14

Patients and referring clinicians can compare pathology-review processes, access to lymphoma specialists, transplantation capacity, clinical-trial eligibility, telehealth availability, travel requirements, insurance participation, and continuity of survivorship care. UCSF's lymphoma program, directed by Lawrence D. Kaplan, includes expertise in Hodgkin lymphoma and HIV-associated lymphoma, while the profile identifies participation in national lymphoma research groups. Those details demonstrate the importance of matching clinical expertise to the patient's medical circumstances. 12

Risks, eligibility, and practical limitations

Advanced therapies can involve strict eligibility rules, specialized monitoring, and substantial logistical demands. Sheba states that its lymphoma CAR T-cell treatment is offered through a research program and that eligibility is assessed individually. International treatment can add travel, language, records-transfer, follow-up, and coordination issues. A hospital's ability to offer a therapy therefore does not mean that the therapy is appropriate, approved for every indication, or available to every patient. 11

A balanced hospital comparison should also distinguish institutional reputation from measurable personal relevance. Questions for a consultation include whether the diagnosis will receive expert pathology review, how often the center treats the relevant subtype, which standard and investigational options apply, what monitoring is required, and how care will continue after treatment. NCI designation, national rankings, and specialist profiles are useful evidence points, but treatment decisions require an individualized medical evaluation. 7

Sources

1. Healio, UT MD Anderson ranked nation's top cancer hospital
2. Memorial Sloan Kettering Cancer Center
3. Mayo Clinic, lymphoma care
4. Dana-Farber Cancer Institute, lymphoma
5. Johns Hopkins Medicine, lymphoma
6. Cleveland Clinic, lymphoma care
7. National Cancer Institute, NCI-Designated Cancer Centers
8. City of Hope, lymphoma care
9. Fred Hutchinson Cancer Center, lymphoma
10. University of Chicago Medicine, lymphoma
11. Sheba Medical Center, CAR T-cell therapy for lymphoma
12. UCSF Health, Lawrence D. Kaplan, MD
13. Mass General Brigham, Jeremy S. Abramson, MD, MMSC
14. OU Health Stephenson Cancer Center, lymphoma